logo

Myokardia Inc (MYOK)



Trade MYOK now with
  Date
  Headline
11/4/2020 7:06:59 AM Bristol Myers Squibb, MyoKardia Report Expiration Of HSR Act Waiting Period
10/5/2020 6:33:37 AM Bristol Myers Squibb To Acquire MyoKardia For $13.1 Bln Cash
7/23/2020 4:14:12 PM MyoKardia Says FDA Granted Breakthrough Therapy Designation To Mavacamten
7/21/2020 8:02:13 AM MyoKardia, Fulcrum Therapeutics Enter Strategic Collaboration And License Agreement
7/6/2020 8:08:21 AM MyoKardia Appoints Denelle Waynick As General Counsel And Corporate Secretary
5/11/2020 7:42:05 AM MyoKardia Announces Positive Topline Data From Phase 3 Pivotal EXPLORER-HCM Clinical Trial Of Mavacamten
9/3/2019 8:15:38 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $90 Price Target
5/13/2019 6:24:17 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $87 Price Target
11/13/2018 7:24:15 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $77 Price Target
11/9/2018 8:55:32 AM Wedbush Is Increasing MyoKardia Inc (MYOK) FY18 Estimate To -1.97 From -2.20
11/9/2018 8:55:13 AM Wedbush Is Raising MyoKardia Inc (MYOK) Q4 18 Estimate To -0.58 From -0.65
11/9/2018 8:54:57 AM Wedbush Is Increasing MyoKardia Inc (MYOK) Q3 18 Estimate To -0.39 From -0.57
11/9/2018 8:54:32 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $77 Price Target
8/9/2018 9:50:09 AM Wedbush Is Increasing MyoKardia Inc (MYOK) FY18 Estimate To -2.22 From -2.45
8/9/2018 9:49:51 AM Wedbush Is Raising MyoKardia Inc (MYOK) Q4 18 Estimate To -0.64 From -0.72